[go: up one dir, main page]

WO1992004916A3 - Agents sous forme de particules - Google Patents

Agents sous forme de particules Download PDF

Info

Publication number
WO1992004916A3
WO1992004916A3 PCT/EP1991/001780 EP9101780W WO9204916A3 WO 1992004916 A3 WO1992004916 A3 WO 1992004916A3 EP 9101780 W EP9101780 W EP 9101780W WO 9204916 A3 WO9204916 A3 WO 9204916A3
Authority
WO
WIPO (PCT)
Prior art keywords
particulate agents
diagnostic
vascularized
prophylaxis
therapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP1991/001780
Other languages
English (en)
Other versions
WO1992004916A2 (fr
Inventor
Aaron Gershon Filler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
St Georges Enterprises Ltd
Original Assignee
St Georges Enterprises Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB909020075A external-priority patent/GB9020075D0/en
Priority claimed from GB909027293A external-priority patent/GB9027293D0/en
Priority claimed from GB919100233A external-priority patent/GB9100233D0/en
Priority claimed from GB919100981A external-priority patent/GB9100981D0/en
Priority claimed from GB919102146A external-priority patent/GB9102146D0/en
Priority claimed from GB919110876A external-priority patent/GB9110876D0/en
Priority claimed from GB919116373A external-priority patent/GB9116373D0/en
Priority claimed from GB919117851A external-priority patent/GB9117851D0/en
Priority claimed from GB919118676A external-priority patent/GB9118676D0/en
Priority to EP91916129A priority Critical patent/EP0548157B1/fr
Priority to DE69129463T priority patent/DE69129463T2/de
Application filed by St Georges Enterprises Ltd filed Critical St Georges Enterprises Ltd
Publication of WO1992004916A2 publication Critical patent/WO1992004916A2/fr
Publication of WO1992004916A3 publication Critical patent/WO1992004916A3/fr
Anticipated expiration legal-status Critical
Priority to US10/015,162 priority patent/US6919067B2/en
Ceased legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
    • A61K49/1851—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule
    • A61K49/1863—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule the organic macromolecular compound being a polysaccharide or derivative thereof, e.g. chitosan, chitin, cellulose, pectin, starch

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nanotechnology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Ceramic Engineering (AREA)
  • Biophysics (AREA)
  • Medical Informatics (AREA)
  • Immunology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biotechnology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

L'invention décrit un nouveau moyen pharmaceutique servant à des fins thérapeutiques ou prophylactiques ou bien à contribuer à des opérations chirurgicales ou diagnostiques effectuées sur le corps humain, par endocytose neuronale et transport axonal, suivant l'administration pharmaceutique dans un tissu vascularisé et à innvervation périphérique, par exemple, d'injections intramusculaires d'une molécule d'adhésion sur un nerf en particule couplée, comprenant une substance efficace sur le plan physiologique ou un marqueur diagnostique.
PCT/EP1991/001780 1990-09-14 1991-09-13 Agents sous forme de particules Ceased WO1992004916A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
DE69129463T DE69129463T2 (de) 1990-09-14 1991-09-13 Verwendung von substanzen in partikelform
EP91916129A EP0548157B1 (fr) 1990-09-14 1991-09-13 Utilisation d'agents sous forme de particules
US10/015,162 US6919067B2 (en) 1991-09-13 2001-12-11 Compositions comprising a tissue glue and therapeutic agents

Applications Claiming Priority (20)

Application Number Priority Date Filing Date Title
GB9020075.9 1990-09-14
GB909020075A GB9020075D0 (en) 1990-09-14 1990-09-14 Contrast agents for magnetic resonance imaging of axonal transport
GB9023580.5 1990-10-30
GB909023580A GB9023580D0 (en) 1990-09-14 1990-10-30 Contrast agents for magnetic resonance imaging of axonal transport
GB9027293.1 1990-12-17
GB909027293A GB9027293D0 (en) 1990-09-14 1990-12-17 Ferrite particles for tracer imaging and treatment
GB919100233A GB9100233D0 (en) 1990-09-14 1991-01-07 Metal oxide particles for medical use
GB9100233.7 1991-01-07
GB919100981A GB9100981D0 (en) 1990-09-14 1991-01-16 Metal oxide particles for medical use
GB9100981.1 1991-01-16
GB9102146.9 1991-01-31
GB919102146A GB9102146D0 (en) 1990-09-14 1991-01-31 Particles for delivery via vascular,lymphatic and neural routes
GB9110876.1 1991-05-20
GB919110876A GB9110876D0 (en) 1990-09-14 1991-05-20 Particles for delivery via vascular lymphatic and neural routes
GB9116373.3 1991-07-30
GB919116373A GB9116373D0 (en) 1990-09-14 1991-07-30 Affinity purified,filter sterilized,targeted nanoparticles for delivery by intraneural,vascular and lymphatic routes
GB9117851.7 1991-08-19
GB919117851A GB9117851D0 (en) 1990-09-14 1991-08-19 Affinity purified, filter sterilized, targeted nanoparticles for delivery by intraneural, vascular, and lymphatic routes
GB9118676.7 1991-08-30
GB919118676A GB9118676D0 (en) 1990-09-14 1991-08-30 Affinity purified,filter sterilized,targeted nanoparticles for delivery by intraneural,vascular,and lymphatic routes

Related Child Applications (3)

Application Number Title Priority Date Filing Date
US07988919 A-371-Of-International 1993-04-05
US08/473,697 Continuation US5948384A (en) 1990-09-14 1995-06-07 Particulate agents
US08/473,697 Division US5948384A (en) 1990-09-14 1995-06-07 Particulate agents

Publications (2)

Publication Number Publication Date
WO1992004916A2 WO1992004916A2 (fr) 1992-04-02
WO1992004916A3 true WO1992004916A3 (fr) 1992-08-20

Family

ID=27579385

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1991/001780 Ceased WO1992004916A2 (fr) 1990-09-14 1991-09-13 Agents sous forme de particules

Country Status (6)

Country Link
EP (1) EP0548157B1 (fr)
AT (1) ATE166233T1 (fr)
AU (1) AU8514291A (fr)
DE (1) DE69129463T2 (fr)
IE (1) IE913240A1 (fr)
WO (1) WO1992004916A2 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9119762D0 (en) * 1991-09-16 1991-10-30 Filler Aaron G Particulate agents for nmt
US5225282A (en) * 1991-12-13 1993-07-06 Molecular Bioquest, Inc. Biodegradable magnetic microcluster comprising non-magnetic metal or metal oxide particles coated with a functionalized polymer
FR2775435B1 (fr) * 1998-02-27 2000-05-26 Bioalliance Pharma Nanoparticules comprenant au moins un polymere et au moins un compose apte a complexer un ou plusieurs principes actifs
US6372722B1 (en) 2000-01-19 2002-04-16 Genteric, Inc. Method for nucleic acid transfection of cells
CN105381222A (zh) * 2015-12-09 2016-03-09 徐冉 一种防治面肌痉挛的中药组合物及制备方法
CN105381294A (zh) * 2015-12-09 2016-03-09 徐冉 用于医治面神经麻痹的制剂及制法
CN105381295A (zh) * 2015-12-09 2016-03-09 徐冉 一种治疗面肌痉挛的制剂及制备方法
CN105381296A (zh) * 2015-12-09 2016-03-09 徐冉 一种治疗面瘫的祛风通络制剂及制法
US10744212B2 (en) 2016-03-14 2020-08-18 General Electric Company Topical application of nerve labeling dyes for image-guided surgery

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1986001112A1 (fr) * 1984-08-10 1986-02-27 Fox Chase Cancer Center Les microparticules comme agents de contraste dans la production d'images par resonance magnetique nucleaire
WO1988000060A1 (fr) * 1986-07-03 1988-01-14 Advanced Magnetics, Inc. Materiau super paramagnetique biodegradable utilise dans des applications cliniques
WO1989009625A1 (fr) * 1988-04-08 1989-10-19 Cockbain, Julian, Roderick, Michaelson Ameliorations apportees a l'imagerie par resonance magnetique
WO1990001295A1 (fr) * 1988-08-04 1990-02-22 Advanced Magnetics, Incorporated Agents de contraste d'irm de type endocytose induits par recepteur

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1986001112A1 (fr) * 1984-08-10 1986-02-27 Fox Chase Cancer Center Les microparticules comme agents de contraste dans la production d'images par resonance magnetique nucleaire
WO1988000060A1 (fr) * 1986-07-03 1988-01-14 Advanced Magnetics, Inc. Materiau super paramagnetique biodegradable utilise dans des applications cliniques
WO1989009625A1 (fr) * 1988-04-08 1989-10-19 Cockbain, Julian, Roderick, Michaelson Ameliorations apportees a l'imagerie par resonance magnetique
WO1990001295A1 (fr) * 1988-08-04 1990-02-22 Advanced Magnetics, Incorporated Agents de contraste d'irm de type endocytose induits par recepteur

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
STN File Server, File Medline, accession no. 86085167, D. MENETREY: "Retrograde tracing of neural pathways with a protein-gold complex. I. Light microscopic detection after silver intensification", & HISTOCHEMISTRY, 83(5), 1985, 391-5, see the whole abstract *
STN File Server, File Medline, accession no. 87239688, J.E. GALLAGHER et al.: "Sialic acid mediates the initial binding of positively charged inorganic particles to alveolar macrophage membranes", & AM. REV. RESPIR. DIS., 135(6), JUNE 1987, 1345-52, see the whole abstract *

Also Published As

Publication number Publication date
EP0548157B1 (fr) 1998-05-20
EP0548157A1 (fr) 1993-06-30
DE69129463D1 (de) 1998-06-25
IE913240A1 (en) 1992-02-25
AU8514291A (en) 1992-04-15
WO1992004916A2 (fr) 1992-04-02
ATE166233T1 (de) 1998-06-15
DE69129463T2 (de) 1998-09-17

Similar Documents

Publication Publication Date Title
EP0861667A3 (fr) Agents particulaires
CA2184242A1 (fr) Systeme de ciblage d'un medicament, procede de preparation et utilisation de ce medicament
CA2628857A1 (fr) Preparation et methode de traitement de neoplasmes par inhalation
GB2316004B (en) Novel formulations for transdermal delivery of pergolide
CA2064689A1 (fr) Conjugues de proteines ou de peptides stabilises
ATE361093T1 (de) Selektiv auf die leber wirkende pharmazeutisch aktive substanz
AU8696191A (en) Formulations and their use in the treatment of neurological diseases
AU4271496A (en) Particle delivery
DE68925974D1 (de) Konjugate zur steigerung der durchlässigkeit der gefässe
CA2111836A1 (fr) Compositions pharmaceutiques a piegeage de spin et methodes d'utilisation correspondantes
WO1994006449A3 (fr) Regeneration du foie induite par des morphogenes
WO1992004916A3 (fr) Agents sous forme de particules
CA2143610A1 (fr) Utilisation de norastemizole pour le traitement de troubles allergiques
EP0393707A3 (fr) Composés bio-actifs associés à des liposomes et leur utilisation dans des préparations pharmaceutiques
EP1304108A3 (fr) Compositions pour traiter l'arythmie et procédés de traitement
AU8687391A (en) Lithium treatment
AU5643299A (en) Humic acid and its use in the treatment of various conditions
WO1990004977A3 (fr) Traitement de condylomes genitaux a l'aide d'une combinaison d'azote liquide et d'interferon alpha humain d'adn de recombinaison
ATE173405T1 (de) Arzneimittel auf basis von hyaluronsäure
TWI263502B (en) Pharmaceutical preparation for treating ischemic disease of heart or limbs
Walker A double-blind comparative trial of the decanoates of clopenthixol and fluphenazine in the treatment of chronic schizophrenic out-patients
Mantovani et al. Recombinant alpha interferon in the treatment of low-grade non-Hodgkin's lymphoma: results of a cooperative phase II trial in 31 patients
CA2336773A1 (fr) Compose b en tant qu'agent angiogenique combine a des facteurs de croissance humaine
CA2000479A1 (fr) Conjuges accroissant la vasopermeabilite
Belousov et al. Experience using cefpirome in pneumonia

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP NO US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE

AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP NO US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE

WWE Wipo information: entry into national phase

Ref document number: 1991916129

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1991916129

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: CA

WWG Wipo information: grant in national office

Ref document number: 1991916129

Country of ref document: EP